Discover VRTX Stock Forecast for 2025, 2030, 2035, 2040, 2045, 2050, and 2060. Get the latest long-term Vertex Pharmaceuticals Stock (VRTX) price predictions and VRTX price target revenue to R&D.
Key Takeaways: Vertex Pharmaceuticals Stock Price Prediction: According to 21 analysts offering short-term price targets, the average VRTX Pharmaceuticals price target is $475, with a high forecast of $570, and a low estimate of $380. This VRTX stock price represents a 22.39% increase from its current price of $456.95.
Read: STRO Stock Forecast 2025, 2030, 2040 Price Target and Prediction
Table of Contents
What is Vertex Pharmaceuticals Inc.?
Vertex Pharmaceuticals Incorporated is a leading pharmaceutical company dedicated to discovering, developing, and commercializing innovative pharmaceutical products. Specializing in treatments for a range of conditions including cystic fibrosis, cancer, inflammatory bowel disease, autoimmune disorders, and neurological disorders, Vertex is at the forefront of healthcare innovation. With a global presence, Vertex Pharmaceuticals serves the healthcare sector worldwide, striving to improve patient outcomes and quality of life through groundbreaking medical advancements.
Company Profile
| Company | Vertex Pharmaceuticals Incorporated |
|---|---|
| Traded as | Nasdaq: VRTX |
| Industry | Pharmaceuticals, Biotherapeutics |
| Sector | Healthcare (Biopharmaceutical) |
| Headquarters | Boston, Massachusetts, U.S. |
| President and CEO | Reshma Kewalramani |
| Revenue | Increase US$9.87 billion (2023) |
| Number of employees | 5,400 |
| Website | vrtx.com |
Read: VERI Stock Forecast 2025, 2030, 2040 Veritone Analyst Estimate, Price Target
Vertex Pharmaceuticals Inc, (NASDAQ: VRTX) Financial Health
In the latest quarterly financial report of March 2024, Vertex Pharmaceuticals (NASDAQ: VRTX) showcased robust performance, with a notable year-over-year (Y/Y) revenue growth of 13.3%, reaching $2.69 billion. The company also demonstrated impressive profitability, recording a substantial 57.13% increase in net income, totaling $1.1 billion, a remarkable 56.51% rise in diluted earnings per share (EPS) to $4.21.
Moreover, Vertex exhibited a solid net profit margin of 40.87%, underscoring its efficient management of expenses relative to revenue. During the earnings calls, Vertex Pharmaceuticals surpassed expectations, achieving a notable 17.28% beat in EPS and a commendable 4.28% beat in revenue, further solidifying its position as a financially healthy and thriving entity in the pharmaceutical industry.
Related: ABBV Stock Forecast 2025, 2030, 2040 AbbVie Price Prediction
Vertex Pharmaceuticals Inc, (VRTX) Fundamental Analysis
| Previous Close | $450.80 |
| Open | $451.90 |
| Day’s Range | $449.42 – $457.66 |
| 52 Week Range | $320.01 – $457.66 |
| Volume | 1,044,672 |
| Avg. Volume | 1,040,676 |
| Earnings Date | Jul 30, 2024 – Aug 5, 2024 |
| Market Cap (intraday) | $117.917B |
| PE Ratio (TTM) | 0.39 |
| PE Ratio (TTM) | 29.67 |
| EPS (TTM) | $15.40 |
| Forward Dividend & Yield | N/A |
| Ex-Dividend Date | N/A |
| 1y Target Est | $467.71 |
Vertex Pharmaceuticals Incorporated (VRXT) Technical Analysis
According to Technical Ratings, Vertex Pharmaceuticals stock is considered a “Buy” based on its current stock price of $442.00, which is above both the 20-day Simple Moving Average (SMA) of $416.57 and the 50-day SMA of $410.86.
Vertex Pharmaceuticals Stock Price Historical Chart By Trading View
Long-term Vertex Pharmaceuticals Stock (VRTX) Price Forecast for 2025, 2030, 2035, 2040, 2045, 2050, and 2060
According to the latest long-term forecasts VRTX Pharmaceuticals stock price will hit $458 by May 30, 2024, and then reach $590 by the end of 2025. Vertex Pharma will rise to $750 within the year 2029, $1,450 in 2030, $1,900 in 2035, $2,100 in 2040, $ 2,500 in 2045, $3,000 in 2050, and $3,600 in 2060.
| Year | Forecast | Change (%) |
|---|---|---|
| 2025 | $590 | 27.40% |
| 2029 | $750 | 61.95% |
| 2030 | $1,450 | 213.11% |
| 2035 | $1,900 | 310.28% |
| 2040 | $2,100 | 353.47% |
| 2045 | $2,500 | 439.84% |
| 2050 | $3,000 | 547.81% |
| 2060 | $3,600 | 677.37% |
Vertex Pharmaceuticals | VRTX Stock Forecast 2024
According to our latest updates short-term VRTX stock forecast, the value of Vertex Pharmaceuticals Stock (VRTX) shares will rise by 4.81% and reach $ 464.80 per share by May 30, 2024. The current bullish sentiment is based on technical indicators.
Vertex Pharmaceuticals | VRTX Stock Forecast 2025
According to the current Vertex Pharmaceuticals stock forecast, the price in 2025 is expected to reach $590. The average price target for VRTX stock is $550.17, with a low estimate of $480. This represents a 27.40% increase from its current price of $456.95, assuming Vertex Pharmaceuticals shares continue growing at the average yearly rate as they did over the last 10 years.
Vertex Pharmaceuticals | VRTX Stock Forecast 2029
The Nasdaq report gives investors valuable insights into market sentiment and expectations for Vertex Pharmaceuticals stock. VRTX stock is projected to reach an average price target of $455.20 by 2029, with a high estimate of $550 and a low estimate of $325. These figures are derived from analyst price targets compiled over the past three months.
Vertex Pharmaceuticals | VRTX Stock Forecast 2030
| Year | Mid-Year | End-Year | Change |
|---|---|---|---|
| 2030 | $1,396.00 | $1,450 | 213.11% |
Vertex Pharmaceuticals stock (VRTX) price prediction is expected to reach a high price of $1,450 with an average price target for the VRTX stock forecast will reach $1,396.00 per share price by 2030. If Vertex Pharmaceuticals shares continue growing at the average yearly rate as they did over the last 10 years but can experience, a low estimate of $1,180.
Vertex Pharmaceuticals | VRTX Stock Forecast 2035
Vertex Pharmaceuticals (VRTX) stock price targets for 2035 range from $1,900–$1,960.10. This represents an average price target of 353.47% increase from its current price of $456.95, assuming Vertex Pharmaceuticals shares continue growing at the average yearly rate as they did over the last 10 years.
Vertex Pharmaceuticals | VRTX Stock Forecast 2040
In the 2040 forecast, Vertex Pharmaceuticals, Inc. (VRTX) stock is anticipated to surge on a bullish trajectory, with analysts setting an average price target of $2,050.00. This represents a remarkable 353.47% change from its current level. Projections span from a conservative estimate of $1,773.08 to an optimistic high of $2,100.
Vertex Pharmaceuticals | VRTX Stock Forecast 2045
In 2045, Vertex Pharmaceuticals stock forecast, the price in 2045 is expected to reach $2,500. The average price target for VRTX stock is $2,450.00, with a low estimate of $2,280. This represents a 439.84% increase from its current price of $456.95, assuming Vertex Pharmaceuticals shares continue growing at the average yearly rate as they did over the last 10 years.
Vertex Pharmaceuticals | VRTX Stock Forecast 2050
Vertex Pharmaceuticals, Inc. (VRTX) stock forecast will go way up by 2050, aiming for an average of $2,334.06, an increase of +410.79% from its current value. Vertex Pharmaceuticals (VRTX) stock price targets for 2050 range between $2,294.60 on the lower end and $2,336.30 on the high end.
Vertex Pharmaceuticals | VRTX Stock Forecast 2060
Vertex Pharmaceuticals, Inc. Stock (VRTX) is expected to reach an average price of $3,540 in 2030, with a high forecast of $3,600 and a low forecast of $2,633.90. This signifies a 677.37% surge from the last price of $456.95.
Should you invest in Vertex Pharmaceuticals Incorporated (VRTX)?
With 64.29% of analysts recommending Vertex Pharmaceuticals Incorporated (VRTX) as a Strong Buy and 21.43% recommending it as a Buy, it appears favorable to consider investing in the company. Additionally, since 7.14% suggest holding and only 7.14% advise against investing, the overall sentiment leans towards investing in VRTX.
Conclusion, FAQs regarding Vertex Pharmaceuticals stock forecast
Investing in Vertex Pharmaceuticals (VRTX) could be a good idea. Analysts predict strong growth for VRTX stock over the coming years, with price targets indicating substantial increases. With the majority of analysts recommending buying or strongly buying the stock, and considering the company’s solid financial performance, investing in VRTX appears favorable for potential returns in the future.
Is Vertex a good Pharmaceutical company to invest in?
Absolutely, Vertex Pharmaceuticals stands as an excellent choice for investment in the pharmaceutical sector. With a remarkable 36.2% cash flow growth and an anticipated expansion of 5.2% this year, coupled with robust fundamentals, a favorable Zacks Rank, and top-tier Growth and VGM Style Scores
What is the stock market prediction for VRTX in 2025?
According to our analyst’s calculations, VRTX Pharmaceutical’s average price target is $550.17 with a peak estimate of $590 and a min estimate of $425. This charts a 213.11% increase from its current price of $456.95
What is the stock market prediction for VRTX in 2040?
Vertex Pharmaceuticals stock price prediction in 2040 is expected to reach an average price target is $2,050.00 with a high estimate of $590 and a low estimate of $1,773.08.
What is the stock market prediction for VRTX in 2030?
Despite a niche market, Casgevy’s sales could reach $1 billion by 2027 and acme at $2.2 billion by 2030.
Disclaimer: Stock forecasts and earnings estimates are subject to market volatility and should be considered speculative projections. Investors should conduct their research and consult with financial advisors before making investment decisions.
Ashish Dwivedi is the founder and chief editor of MoneyMystica, a top resource for finance, insurance, and share market insights. Driven by a passion for empowering individuals to make informed financial decisions, Ashish uses his extensive knowledge and practical experience to offer clear and actionable advice.
